Clinical Trial Update: MB-CART20.1 Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Miltenyi Biomedicine's MB-CART20.1 Lymphoma trial in relapsed or refractory B-cell non-Hodgkin lymphoma and non-Hodgkin lymphoma has completed Phase 1 and Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MB-CART20.1 Lymphoma

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED